SMITHS-DETECTION
Smiths Detection , a global leader in threat detection and security inspection technologies, announces that it has begun installing 30 HI-SCAN 6040 CTiX carry-on baggage screening systems at Leonardo di Vinci International Airport in Rome. The installation of this world-leading technology reflects the airport’s high standards for passenger service excellence and process automation, having recently been awarded the ACI Best Airport in Europe for the fourth time in the last five years.
Smiths Detection’s HI-SCAN 6040 CTiX is a computed tomography (CT) X-ray scanner producing high-resolution volumetric 3D images for quicker and deeper baggage assessment and low false-alarm rates. The scanners allow for electronics and liquids to remain in bags, speeding up passenger screening and reducing touchpoints.
The combination of the CT X-ray scanners, alongside 45 already supplied Smiths Detection IONSCAN 600 trace detectors, will further improve security and operational efficiency. The IONSCAN 600 is a highly sensitive, non-radioactive, lightweight, portable desktop system that detects and identifies trace amounts of explosives and narcotics.
The HI-SCAN 6040 CTiX can be equipped with Smiths Detection’s object recognition software, iCMORE , which uses advanced algorithms to reduce the burden on operators – and potential errors – by automating the detection process for prohibited items.
Stefano Scardigli, Senior Key Account, Smiths Detection said: “We are delighted to supply Leonardo di Vinci Rome International Airport with 30 HI-SCAN 6040 CTiX scanners. Utilising 3D imagery, our scanners offer the advanced screening of carry-on baggage, enhancing security and improving operational efficiency. Being able to leave electronics and liquids in carry-on baggage will help expedite the screening process, especially in light of the well documented staffing pressures at airports around the world.”
Marco Stramaccioni, Chief Executive Officer of ADR Security for Leonardo da Vinci Rome International Airport said: “Aeroporti di Roma looks forward to be a frontrunner for passenger experience and security at Leonardo di Vinci Rome International Airport. As passenger numbers increase, we will be well placed to efficiently screen passengers, reducing the burden on our operators. By harnessing the power of CT technology, we have futureproofed our security checkpoints.”
Smiths Detection’s HI-SCAN 6040 CTiX is certified by the U.S. Transportation Security Administration (TSA) under the Accessible Property Screening System (APSS) program to detection standard 6.2, Level 1, permitting the scanner to operate at an enhanced level with lower false alarm rates, as well as ECAC and STAC EDS CB C3 approval.
###
About the Products
- HI-SCAN 6040 CTiX: https://www.smithsdetection.com/products/hi-scan-6040-ctix/
- IONSCAN 600: https://www.smithsdetection.com/products/ionscan-600/
- iCMORE: https://www.smithsdetection.com/products/icmore/
About Smiths Detection
Smiths Detection, a division of Smiths Group, is a global leader in inspection and detection technologies for the air transport, ports and borders, armed forces and urban security markets. With more than 70 years of experience in the field, we offer the necessary solutions to protect society from the threats posed by explosives, prohibited weapons, contraband, toxic chemical agents and narcotics.
Our mission is simple: to ensure the security, peace of mind and freedom of movement on which the world depends.
Please visit http://www.smithsdetection.com/ for further information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220808005455/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom